MYL - マイラン (Mylan N.V.) マイラン

 MYLのチャート


 MYLの企業情報

symbol MYL
会社名 Mylan NV (マイラン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 マイラン(Mylan N.V.)は製薬会社である。同社はジェネリック医薬品、ブランド及び店頭商品(OTC)医薬品を開発・ライセンス供与・製造・販売する。同社は北米、欧州、その他の地域の3つのセグメントを通じて事業を展開する。同社の「Cold-EEZE」ブランドは米国ではロゼンジ、ガム、経口スプレー、カプレット、QuickMelts、経口液体剤形等で販売されるOTCコールド・レメディが含まれる。北米事業は主に、錠剤、カプセル剤、注射剤、経皮パッチ剤、ゲル剤、噴霧剤とクリーム剤または軟膏剤で医薬品を開発、製造、販売する。欧州事業は医薬品原薬(API)等の国際非営利団体名(INN)で医薬品を販売する。その他の地域事業は主にインド、オーストラリア、日本、ニュージーランドでの事業を含む。   マイランは米国の製薬会社。錠剤、カプセル剤、貼付剤のジェネリック医薬品、抗レトロウイルス薬などの医薬品有効成分(原薬)、急性アレルギ―治療用の自己注射薬「エピペン」、慢性閉塞性肺疾患向け吸入剤「パ―フォロミスト」、精神疾患治療薬などを提供。1100品目を越える医薬品を約150の国と地域で販売。   Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
本社所在地 Building 4 Trident Place Mosquito Way Hatfield Hertfordshire 15317 GBR
代表者氏名 Rajiv Malik ラジジ・マリク
代表者役職名 President Executive Director
電話番号 +44 1707-85-3000
設立年月日 1970年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 35000人
url www.mylan.com
nasdaq_url https://www.nasdaq.com/symbol/myl
adr_tso
EBITDA EBITDA(百万ドル) 3708.8
終値(lastsale) 35.3
時価総額(marketcap) 18199524066.2
時価総額 時価総額(百万ドル) 16807.49
売上高 売上高(百万ドル) 11718.8
企業価値(EV) 企業価値(EV)(百万ドル) 31159.39
当期純利益 当期純利益(百万ドル) 585.80000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Mylan NV revenues decreased 3% to $5.49B. Net income decreased 66% to $124.6M. Revenues reflect North America segment decrease of 19% to $2.05B Northern America segment decrease of 7% to $2.35B. Net income also reflects North America segment income decrease of 32% to $835.3M Rest of World segment income decrease of 7% to $280.6M Northern America segment income decrease of 11% to $1.1B.

 MYLのテクニカル分析


 MYLのニュース

   Active Pharmaceutical Ingredients (API) Market : COVID-19 Impact Analysis with Size, Share, Industry Outlook and Future Scope, Leading Players are Pfizer, Novartis AG, Sanofi, Eli Lilly and Company., Mylan N.V., Piramal Pharma Solutions  2020/11/17 11:13:41 OpenPR
Analysis and discussion of important industry trends, market size, and market share estimates are revealed in the Active Pharmaceutical Ingredients (API) Market research report. Further, manufacturer can adjust production according to the conditions of demand which are analyzed here. The
   Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan  2020/11/16 12:30:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitude to our Upjohn colleagues for their dedicati
   PDE Inhibitors Market To 2020 - 2027 Analysis | Leading Players, Industry Updates, Future Growth | Mylan N.V., Eli Lilly and Company, AstraZeneca  2020/11/12 12:00:25 OpenPR
PDE Inhibitors Market research report deals with many parameters in depth to satisfy the requirements of business or clients. Market segmentation is also covered in detail in this report by considering several aspects that is sure to help businesses out
   Osteonecrosis Treatment Market Analysis by Atnahs, Teva Pharmaceutical Industries Ltd, Mylan N.V, Integra LifeSciences Corporation  2020/11/11 18:26:43 OpenPR
Osteonecrosis Treatment Market By Therapy (Stem Cell Therapy, Joint Replacement Therapy), Treatment (Medication, Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Direct, Online Pharmacy, Retailers and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific,
   Global Developmental Dyspraxia Drug Market In Deep Analysis, Expert Reviews and Precise Outlook 2027 || Eli Lily & Company, Novartis AG, Mylan N.V., Tris Pharma, Inc  2020/11/11 14:21:38 OpenPR
Databridgemarketresearch.com Present “Global Developmental Dyspraxia Drug Market– Industry Trends and Forecast to 2027” new report to its research database. The report spread No of pages: 350 No of Figures: 60 No of Tables: 220 in it. Global Developmental Dyspraxia Drug
   Active Pharmaceutical Ingredients (API) Market : COVID-19 Impact Analysis with Size, Share, Industry Outlook and Future Scope, Leading Players are Pfizer, Novartis AG, Sanofi, Eli Lilly and Company., Mylan N.V., Piramal Pharma Solutions  2020/11/17 11:13:41 OpenPR
Analysis and discussion of important industry trends, market size, and market share estimates are revealed in the Active Pharmaceutical Ingredients (API) Market research report. Further, manufacturer can adjust production according to the conditions of demand which are analyzed here. The
   Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan  2020/11/16 12:30:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitude to our Upjohn colleagues for their dedicati
   PDE Inhibitors Market To 2020 - 2027 Analysis | Leading Players, Industry Updates, Future Growth | Mylan N.V., Eli Lilly and Company, AstraZeneca  2020/11/12 12:00:25 OpenPR
PDE Inhibitors Market research report deals with many parameters in depth to satisfy the requirements of business or clients. Market segmentation is also covered in detail in this report by considering several aspects that is sure to help businesses out
   Osteonecrosis Treatment Market Analysis by Atnahs, Teva Pharmaceutical Industries Ltd, Mylan N.V, Integra LifeSciences Corporation  2020/11/11 18:26:43 OpenPR
Osteonecrosis Treatment Market By Therapy (Stem Cell Therapy, Joint Replacement Therapy), Treatment (Medication, Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Direct, Online Pharmacy, Retailers and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific,
   Global Developmental Dyspraxia Drug Market In Deep Analysis, Expert Reviews and Precise Outlook 2027 || Eli Lily & Company, Novartis AG, Mylan N.V., Tris Pharma, Inc  2020/11/11 14:21:38 OpenPR
Databridgemarketresearch.com Present “Global Developmental Dyspraxia Drug Market– Industry Trends and Forecast to 2027” new report to its research database. The report spread No of pages: 350 No of Figures: 60 No of Tables: 220 in it. Global Developmental Dyspraxia Drug
   Active Pharmaceutical Ingredients (API) Market : COVID-19 Impact Analysis with Size, Share, Industry Outlook and Future Scope, Leading Players are Pfizer, Novartis AG, Sanofi, Eli Lilly and Company., Mylan N.V., Piramal Pharma Solutions  2020/11/17 11:13:41 OpenPR
Analysis and discussion of important industry trends, market size, and market share estimates are revealed in the Active Pharmaceutical Ingredients (API) Market research report. Further, manufacturer can adjust production according to the conditions of demand which are analyzed here. The
   Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan  2020/11/16 12:30:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitude to our Upjohn colleagues for their dedicati
   PDE Inhibitors Market To 2020 - 2027 Analysis | Leading Players, Industry Updates, Future Growth | Mylan N.V., Eli Lilly and Company, AstraZeneca  2020/11/12 12:00:25 OpenPR
PDE Inhibitors Market research report deals with many parameters in depth to satisfy the requirements of business or clients. Market segmentation is also covered in detail in this report by considering several aspects that is sure to help businesses out
   Osteonecrosis Treatment Market Analysis by Atnahs, Teva Pharmaceutical Industries Ltd, Mylan N.V, Integra LifeSciences Corporation  2020/11/11 18:26:43 OpenPR
Osteonecrosis Treatment Market By Therapy (Stem Cell Therapy, Joint Replacement Therapy), Treatment (Medication, Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Direct, Online Pharmacy, Retailers and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific,
   Global Developmental Dyspraxia Drug Market In Deep Analysis, Expert Reviews and Precise Outlook 2027 || Eli Lily & Company, Novartis AG, Mylan N.V., Tris Pharma, Inc  2020/11/11 14:21:38 OpenPR
Databridgemarketresearch.com Present “Global Developmental Dyspraxia Drug Market– Industry Trends and Forecast to 2027” new report to its research database. The report spread No of pages: 350 No of Figures: 60 No of Tables: 220 in it. Global Developmental Dyspraxia Drug

 関連キーワード  (医薬品 米国株 マイラン MYL Mylan N.V.)

 twitter  (公式ツイッターやCEOツイッターなど)